OPGN - OpGen, Inc.
| Previous Close | 0.2850 |
| Open | 0.2704 |
| Bid | 0.2408 x 800 |
| Ask | 0.2850 x 900 |
| Day's Range | 0.2600 - 0.2899 |
| 52 Week Range | 0.2100 - 2.4100 |
| Volume | 22,292 |
| Avg. Volume | 455,690 |
| Market Cap | 5.07M |
| Beta (3Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3050 |
| Earnings Date | Nov 11, 2019 - Nov 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
- Thomson Reuters StreetEvents
Edited Transcript of OPGN earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 OpGen Inc Earnings Call
- GlobeNewswire
OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update
Revenue up 28% Quarter-over-Quarter Progression of 510(k) submission to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates Conference call to be.
- American City Business Journals
Germantown biopharma regains compliance with Nasdaq
The Nasdaq Hearings Panel concluded Neuralstem showed compliance by meeting the minimum $1 bid price requirement.
- Zacks
Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
OpGen Announces Date of Second Quarter 2019 Financial Results Conference Call
GAITHERSBURG, Md., July 30, 2019 -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its second quarter 2019 financial results after the close of the.
- Zacks
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- American City Business Journals
Germantown stem cell therapy company proposes $7M offering amid delisting threat
The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.
- GlobeNewswire
OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy
The study tested 531 remnant urine specimens from Beth Israel Deaconess Medical Center, Geisinger, and Intermountain Healthcare with the Acuitas AMR Gene Panel (For Research Use Only ‘RUO’), to detect five pathogens and 47 antibiotic resistance genes common to urinary tract infections (UTI). Results for the Acuitas AMR Gene Panel (RUO) were produced in less than three hours.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For June 14
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ArQule, Inc. (NASDAQ: ARQL ) shares were up ...
- GlobeNewswire
OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
The presentation will include a comparative analysis of Acuitas Lighthouse and Whole Genome Sequencing (WGS) for Carbapenemase-producing organisms (CPO) in an outbreak investigation conducted by the New York State Department of Health’s Wadsworth Center. The Acuitas Lighthouse data will be shown concordant to WGS but with a faster turnaround time suggesting that Acuitas AMR Gene Panel and Acuitas Lighthouse can be used as front-line tools in clinical settings for transmission and outbreak detection. Also at the meeting, data from a clinical verification study for the Acuitas AMR Gene Panel test for urine will be presented by Geisinger. In this study, over 500 of the remnant urine specimens collected and tested at Beth Israel Deaconess Medical Center (BIDMC), Geisinger, and Intermountain Healthcare were analyzed. The data demonstrate that the Acuitas AMR Gene Panel had greater than 90% agreement with quantitative culture for semi-quantitative pathogen detection and Acuitas Lighthouse phenotype predictions had greater than 90% average total agreement with antibiotic susceptibility testing for E. coli and K. pneumoniae, the most common pathogens that cause urinary tract infections (UTI).
- Thomson Reuters StreetEvents
Edited Transcript of OPGN earnings conference call or presentation 14-May-19 8:30pm GMT
Q1 2019 OpGen Inc Earnings Call
- Zacks
OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -24.24% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
OpGen Reports First Quarter 2019 Financial Results and Provides Business Update
Submission of 510(k) application to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates Revenue up 21% Quarter-over-Quarter Conference call to.
- GlobeNewswire
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
OpGen, Inc. (OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance for its Acuitas AMR Gene Panel test for the detection of antimicrobial resistance genes in bacterial isolates. The Acuitas AMR Gene Panel is a new molecular test developed by OpGen and is designed to detect 47 antibiotic-resistance genes in less than three hours from bacterial isolates.
- Zacks
Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Teladoc's Partnership to Form Pediatric Telehealth Platform
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
- GlobeNewswire
OpGen Announces Closing of Public Offering of Common Stock
GAITHERSBURG, Md., March 29, 2019 -- OpGen, Inc. (Nasdaq: OPGN) announced today the closing of its previously announced underwritten public offering of 9 million shares of its.
- GlobeNewswire
OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal
GAITHERSBURG, Md., March 28, 2019 -- OpGen, Inc. (Nasdaq: OPGN) announced today that data supporting prediction of antibiotic resistance using the company’s Acuitas® AMR Gene.
- GlobeNewswire
OpGen Announces Pricing of a $5.4 Million Public Offering of Common Stock
The company also granted the underwriters a 45-day option to acquire an additional 1,350,000 shares to cover overallotments in connection with the offering. The gross proceeds of the offering are expected to be approximately $5.4 million, prior to deducting underwriting discounts and other estimated offering expenses. OpGen anticipates using the net proceeds of this offering for research and development and regulatory activities in support of the company’s anticipated FDA 510(k) submissions for the Acuitas® AMR Gene Panel test and the Acuitas Lighthouse® Software, commercialization of the Acuitas RUO products and Acuitas in vitro diagnostic products following receipt of FDA clearance, and investments in manufacturing and operations relating to sales of the company’s products.
- GlobeNewswire
OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
GAITHERSBURG, Md., March 25, 2019 -- OpGen, Inc. (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of.
- Thomson Reuters StreetEvents
Edited Transcript of OPGN earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 OpGen Inc Earnings Call
- GuruFocus.com
OpGen Inc (OPGN) Files 10-K for the Fiscal Year Ended on December 31, 2018
OpGen Inc is an precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease. Warning! GuruFocus has detected 1 Warning Sign with OPGN. For the last quarter OpGen Inc reported a revenue of $0.55 million, compared with the revenue of $0.75 million during the same period a year ago.
- GlobeNewswire
OpGen Reports Fourth Quarter and 2018 Financial Results and Provides Business Update
GAITHERSBURG, Md., Feb. 26, 2019 -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and 12 months ended December 31, 2018 and provided a.
- GlobeNewswire
OpGen Appoints R. Don Elsey to Board of Directors
GAITHERSBURG, Md., Feb. 25, 2019 -- OpGen, Inc. (NASDAQ: OPGN) announces the appointment R. Don Elsey to the company’s board of directors and audit committee, effective.
